Results 151 to 160 of about 29,609 (266)

Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS‐DAI)

open access: yesArthritis Care &Research, Accepted Article.
Objective VEXAS syndrome is characterized by a complex spectrum of inflammatory and hematologic manifestations. Clinical research to identify effective therapies is urgently needed but is hindered by the lack of validated outcome measures. A VEXAS‐specific disease activity index (DAI) is an essential tool for reliably capturing changes in disease ...
Kevin Byram   +25 more
wiley   +1 more source

Longitudinal Changes in Adiposity After a Youth Sport‐Related Knee Injury: Informing Posttraumatic Osteoarthritis Prevention

open access: yesArthritis Care &Research, EarlyView.
Objective Youth who experience a sport‐related knee injury have elevated odds of becoming overweight or developing obesity in 3 to 10 years, compounding their risk for posttraumatic osteoarthritis (PTOA). To inform prevention strategies, this study compared patterns of adiposity change between youth with a sport‐related knee injury and uninjured youth ...
Justin M. Losciale   +6 more
wiley   +1 more source

Clinician and patient factors associated with long‐term glucocorticoid use in people with rheumatoid arthritis on advanced therapies

open access: yesArthritis Care &Research, Accepted Article.
Background Despite guideline recommendations, long‐term glucocorticoid (GC) use is common in rheumatoid arthritis (RA). We conducted a clinician survey nested within a large registry to identify patient and clinician factors associated with GC use. Methods Clinicians contributing patients to the CorEvitas Rheumatoid Arthritis registry were surveyed ...
Michael D. George   +7 more
wiley   +1 more source

Short‐term response to biologic therapy in psoriatic arthritis (PsA) is not influenced by disease duration at initiation of therapy

open access: yesArthritis Care &Research, Accepted Article.
Objectives We aimed to determine whether the short‐term response to biologics in biologic‐naïve psoriatic arthritis (PsA) is better in patients initiating biologic treatment early in the disease course. Methods PsA patients who started biologic therapy from the year 2000 to 2025 were included for analysis. Patients considered in the early treatment (ET)
Sung Min Cho   +4 more
wiley   +1 more source

Impact of Six‐Month Monitoring Compared to Three‐Month Monitoring of Laboratories During Methotrexate Therapy

open access: yesArthritis Care &Research, EarlyView.
Objective To evaluate whether extending the American College of Rheumatology–recommended monitoring interval for complete blood count and liver function tests in patients receiving methotrexate (MTX) affects timely detection of medication‐related toxicity.
Spencer Simko   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy